Merck’s Welireg receives European approval for two indications
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
No safety signals related to the vaccine candidate were identified
Offers affordable, high-quality solutions for diabetes care
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Subscribe To Our Newsletter & Stay Updated